Insider Trading Alert - TECH, PERY And BSFT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 9, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $352.00 to $81,483,250.00.

Highlighted Stocks Traded by Insiders:

Bio-Techne (TECH) - FREE Research Report

Steer Randolph C, who is Director at Bio-Techne, sold 1,000 shares at $99.39 on June 9, 2015. Following this transaction, the Director owned 1,000 shares meaning that the stake was reduced by 50% with the 1,000-share transaction.

The shares most recently traded at $99.10, down $0.29, or 0.29% since the insider transaction. Historical insider transactions for Bio-Techne go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Bio-Techne has been 187,500 shares per day over the past 30 days. Bio-Techne has a market cap of $3.7 billion and is part of the health care sector and drugs industry. Shares are up 7.5% year-to-date as of the close of trading on Tuesday.

Bio-Techne Corporation develops, manufactures, and sells biotechnology products and clinical diagnostic controls worldwide. It operates in two segments, Biotechnology and Clinical Controls. The stock currently has a dividend yield of 1.29%. The company has a P/E ratio of 34.0. Currently, there are 4 analysts who rate Bio-Techne a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TECH - FREE

TheStreet Quant Ratings rates Bio-Techne as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bio-Techne Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perry Ellis International (PERY) - FREE Research Report

Britt Anita D, who is Chief Financial Officer at Perry Ellis International, sold 7,092 shares at $25.46 on June 9, 2015. Following this transaction, the Chief Financial Officer owned 23,288 shares meaning that the stake was reduced by 23.34% with the 7,092-share transaction.

Shade Cory, who is EVP, GC and Secretary at Perry Ellis International, sold 3,500 shares at $25.25 on June 9, 2015. Following this transaction, the EVP, GC and Secretary owned 16,052 shares meaning that the stake was reduced by 17.9% with the 3,500-share transaction.

The shares most recently traded at $24.87, down $0.38, or 1.53% since the insider transaction. Historical insider transactions for Perry Ellis International go as follows:

  • 4-Week # shares sold: 18,027
  • 12-Week # shares sold: 18,027
  • 24-Week # shares sold: 18,027

The average volume for Perry Ellis International has been 119,100 shares per day over the past 30 days. Perry Ellis International has a market cap of $389.9 million and is part of the consumer goods sector and consumer non-durables industry. Shares are down 4.09% year-to-date as of the close of trading on Tuesday.

Perry Ellis International, Inc. designs, sources, markets, and licenses apparel products. The company has a P/E ratio of 9.6. Currently, there is 1 analyst who rates Perry Ellis International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PERY - FREE

TheStreet Quant Ratings rates Perry Ellis International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Perry Ellis International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BroadSoft (BSFT) - FREE Research Report

Tholen James Albert, who is Chief Financial Officer at BroadSoft, sold 45,137 shares at $37.36 on June 9, 2015. Following this transaction, the Chief Financial Officer owned 45,168 shares meaning that the stake was reduced by 49.98% with the 45,137-share transaction.

The shares most recently traded at $37.94, up $0.58, or 1.53% since the insider transaction. Historical insider transactions for BroadSoft go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 16,002
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 22,832

The average volume for BroadSoft has been 307,100 shares per day over the past 30 days. BroadSoft has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are up 29.19% year-to-date as of the close of trading on Tuesday.

BroadSoft, Inc. The company has a P/E ratio of 168.4. Currently, there are 5 analysts who rate BroadSoft a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSFT - FREE

TheStreet Quant Ratings rates BroadSoft as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full BroadSoft Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria

Here's a Look at 5 Stocks to Avoid

Here's a Look at 5 Stocks to Avoid

Bio-Techne (TECH) Showing Signs Of Being Strong And Under The Radar

Bio-Techne (TECH) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas: Bio-Techne (TECH) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Bio-Techne (TECH) Is Today's "Barbarian At The Gate" Stock